Notice2024-07988
Notice Pursuant to the National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc.
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 16, 2024
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 74 (Tuesday, April 16, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 74 (Tuesday, April 16, 2024)]
[Notices]
[Page 26926]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-07988]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Subcutaneous Drug Development & Delivery
Consortium, Inc.
Notice is hereby given that on February 2, 2024, pursuant to
section 6(a) of the Act of the National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301 et seq. (``the Act''),
Subcutaneous Drug Development & Delivery Consortium, Inc. (``SC
Consortium'') has filed written notifications simultaneously with the
Attorney General and the Federal Trade Commission disclosing changes in
its membership. The notifications were filed for the purpose of
extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Eli Lilly and Company, Indianapolis, IN; and
Kal[eacute]o, Inc., Richmond, VA, have withdrawn as parties to this
venture.
No other changes have been made in the membership or the planned
activity of the group research project. Membership in this group
research project remains open and Subcutaneous Drug Development &
Delivery Consortium, Inc. intends to file additional written
notifications disclosing all changes in membership.
On October 26, 2020, Subcutaneous Drug Development & Delivery
Consortium, Inc. filed its original notification pursuant to section
6(a) of the Act. The Department of Justice published a notice in the
Federal Register pursuant to section 6(b) of the Act on December 3,
2020 (85 FR 78148).
The last notification was filed with the Department on June 23,
2023. A notice was published in the Federal Register pursuant to
section 6(b) of the Act on August 23, 2023 (88 FR 57479).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-07988 Filed 4-15-24; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on April 16, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.